Condition
Germline BRCA1 Gene Mutation
Total Trials
6
Recruiting
2
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Recruiting2
Active Not Recruiting2
Terminated1
Unknown1
Clinical Trials (6)
Showing 6 of 6 trials
NCT04584255Phase 2Active Not Recruiting
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
NCT07436312Not ApplicableRecruiting
Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer
NCT04090567Phase 2Recruiting
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT04585074Active Not Recruiting
Prospective Study of MAstectomy With Reconstruction Including Robot Endoscopic Surgery
NCT04668521Terminated
Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection
NCT04983628Unknown
Molecular Profiling in Prostate Cancer
Showing all 6 trials